These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R Hum Gene Ther; 2011 Nov; 22(11):1343-53. PubMed ID: 21366404 [TBL] [Abstract][Full Text] [Related]
7. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Diaz RM; Galivo F; Kottke T; Wongthida P; Qiao J; Thompson J; Valdes M; Barber G; Vile RG Cancer Res; 2007 Mar; 67(6):2840-8. PubMed ID: 17363607 [TBL] [Abstract][Full Text] [Related]
8. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. Nelson A; Gebremeskel S; Lichty BD; Johnston B J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474 [TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment. Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741 [TBL] [Abstract][Full Text] [Related]
10. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032 [TBL] [Abstract][Full Text] [Related]